Sep / 2025

OncoDaily IO OncoDaily GI Hemostasis Today

Insight

Oct 27, 2023 3:39 am

Oct 26, 2023 10:46 pm

Oct 26, 2023 10:32 pm

Oct 25, 2023 7:02 pm

Oct 25, 2023 6:04 pm

Oct 25, 2023 5:57 pm

Oct 25, 2023 5:52 pm

Oct 25, 2023 5:27 pm

Oct 25, 2023 5:23 pm

Oct 24, 2023 1:44 pm

…

770

…

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Insight

2023 edition recommendations for the Global Curriculum for Training in Medical Oncology – ESMO

Daniel Flora: Promising data emerging from the BLUE-C colon cancer screening trial

Enrique Soto: The new ESMO and ASCO Global Curriculum in Medical Oncology is now online in Journal of European Society for Medical Oncology and JCO Global Oncology

Amalya Sargsyan: ESMO23 – Advances in EGFR mutated NSCLC

Talha Badar: Moving immunotherapy upfront in B-cell ALL

Tian Zhang: Discussed by Sandhu Shahneen — we should likely wait for PSA recurrence before salvage radiation

Ilya Tsimafeyeu: Patients with metastatic renal cell carcinoma and high fibrinogen levels who received nivolumab had worse overall survival

Tom Powles: TAR-210 releases Erdafitinib slowly into the bladder by a novel release system

Ishwaria Subbiah: If life’s in the journey and not the endpoint, then preparing our patients and caregivers for the EVP journey is the top priority!

MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone – MD Anderson Cancer Center

Headlines

Insight

2023 edition recommendations for the Global Curriculum for Training in Medical Oncology – ESMO

Daniel Flora: Promising data emerging from the BLUE-C colon cancer screening trial

Enrique Soto: The new ESMO and ASCO Global Curriculum in Medical Oncology is now online in Journal of European Society for Medical Oncology and JCO Global Oncology

Amalya Sargsyan: ESMO23 – Advances in EGFR mutated NSCLC

Talha Badar: Moving immunotherapy upfront in B-cell ALL

Tian Zhang: Discussed by Sandhu Shahneen — we should likely wait for PSA recurrence before salvage radiation

Ilya Tsimafeyeu: Patients with metastatic renal cell carcinoma and high fibrinogen levels who received nivolumab had worse overall survival

Tom Powles: TAR-210 releases Erdafitinib slowly into the bladder by a novel release system

Ishwaria Subbiah: If life’s in the journey and not the endpoint, then preparing our patients and caregivers for the EVP journey is the top priority!

MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone – MD Anderson Cancer Center

Headlines

OncoDaily

Oncology

cancer

fight against cancer

Global fight against cancer

cancer care

Breast Cancer

ASCO

Lung cancer

Cancer research

MD Anderson Cancer Center

cancer awareness

NSCLC

ESMO

immunotherapy

cancer treatment

Research

ASCO24

Headlines

colorectal cancer

Childhood Cancer

prostate cancer

AACR

clinical trials

FDA

Dana-Farber Cancer Institute

UICC

American Cancer Society

European Cancer Organisation

NCI

National Cancer Institute

healthcare

SIOP

ASCO25

chemotherapy

Vivek Subbiah

AI

American Society of Clinical Oncology

Paolo Tarantino

IASLC

WHO

Robert Orlowski

multiple myeloma

Memorial Sloan Kettering Cancer Center

Zainab Shinkafi-Bagudu

radiation oncology

Myeloma Paper of the Day

cervical cancer

Myeloma

patient care

European School of Oncology

Sitemap